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Abstract
Inflammatory bowel disease (IBD) is characterised by an inappropriate chronic immune response against resident gut microbes. This may be
on account of distinct changes in the gut microbiota termed as dysbiosis. The role of fungi in this altered luminal environment has been scarcely
reported. We studied the fungal microbiome in de-novo paediatric IBD patients utilising next generation sequencing and compared with adult
disease and normal controls. We report a distinct difference in fungal species with Ascomycota predominating in control subjects compared to
Basidiomycota dominance in children with IBD, which could be as a result of altered tolerance in these patients.
© 2015 The Authors. Published by Elsevier Masson SAS on behalf of Institut Pasteur. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Crohn's disease (CD) and ulcerative colitis (UC) are two
types of inflammatory bowel disease (IBD) of unknown aeti-
ology that result in significant morbidity and health expendi-
ture. Recent data suggests that the prevalence of IBD in
general practice in the UK has exponentially increased to
around 400 per 100,000 [1]. The incidence rate of juvenile
onset IBD has risen by nearly 30% in Scotland over the last
twenty years with a concerning decline in age at presentation
[2]. Paediatric IBD is often considered the ‘purest’ form of
disease without many extraneous influences of adult behaviour
e.g. smoking or disease comorbidity. Studying the aetiological
factors of this form of the disease is perhaps more likely to
further our understanding of the initiating events of these
debilitating conditions [3].
The current paradigm of IBD pathogenesis suggests an
exaggerated immune response against the luminal microbiota
in genetically susceptible individuals. The risk-associated
genes are critical in the innate immune system that recog-
nises and distinguishes pathogens from commensal microor-
ganisms, are involved in the clearance of pathogens or pertain
to the regulation of adaptive immunity [4]. Crucially, a sig-
nificant proportion of individuals with IBD do not have any
evidence of heritable genetic susceptibility indicating that
environmental triggers play an important role in the patho-
genesis of IBD [5]. The gastrointestinal microbiota has come
to the fore in efforts to explain this “pathogenesis gap”. The
normal gastrointestinal tract harbours a complex community
of commensal microbes that are critical to normal physio-
logical functioning. In fact, the microbial gene set within the
gut lumen is 150 times larger than the entire human gene
complement [6]. Traditional culture methods have been un-
successful in characterising the entire microbiota with many
microbes going undetected [7]. Newer molecular methods and
next generation sequence analysis in particular have vastly
enhanced the yield of bacteria and fungi that can be identified
within the gut [8e10].
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In contrast to luminal bacteria, the exact role of colonising
fungi and their pathogenic potential has not been fully
explored. From metagenomic studies it has been established
that 99.1% of the genetic catalogues from the lumen are of
bacterial origin whereas fungal DNA accounts for around
0.02% of the entire mucosa-associated microbiota [6,8,11,12].
It is difficult to ascertain if changes to this component have an
impact on the final genesis of inflammation. However, other
aspects of the immune response may also explain changes that
occur in the fungal microbiome. Anti-Saccharomyces cer-
evisiae antibodies (ASCA) have been found to have a role in
diagnosis, disease phenotype and prognosis, more commonly
found in CD patients compared to UC patients and healthy
controls [13,14]. These patients have also demonstrated a
decreased tolerance to S. cerevisiae [15]. It has now been
shown that CD patients with pattern recognition receptor and
autophagy gene variants, but not those with genetic variants of
IL-23 signalling, were more likely to develop ASCA anti-
bodies [16]. Several questions still remain unanswered in the
aetiopathogenesis of IBD, especially the role of intestinal
fungi in initiating/driving the abnormal inflammation that is
characteristic of IBD. Fungi have received scant attention in
the literature of IBD microbiology to date and warrant specific
and targeted consideration.
2. Methods
2.1. Patient recruitment, biopsy collection and
processing
The 25 children with IBD selected for this study were part
of a cohort of children who had been recruited to the Bacteria
In Scottish Children Undergoing Investigation before Treat-
ment (BISCUIT) study [17]. The inclusion and exclusion
criteria and the modality of assessment of these patients have
been reported previously. In short, these children were strin-
gently evaluated, and only those with documented new onset
IBD who had not received and IBD treatment at any time or
systemic antibiotics in the 3 months prior to their colonoscopy.
The comparator groups comprised of 12 control paediatric
subjects from the same study, two adult patients with a normal
colonoscopy and two adult patients with ulcerative colitis
(UC), who were also part of a previously reported study [18].
Biopsies were taken from a single site, from the distal colon
(rectum/sigmoid), and in the case of IBD subjects macroscopic
inflammation had to be present at the site. 2-3 Biopsies were
collected using standard endoscopic forceps into a sterile
1.5 ml Eppendorf container and placed immediately onto ice
before transfer to 80 C storage.
DNA extraction of mucosal biopsies was performed using
the commercially available Qiagen QIAamp Mini kit (Qiagen,
Crawley, UK) with minor modifications [18]. Ethical approval
was granted by North of Scotland Research Ethics Service on
behalf of all participating centres and written informed con-
sent was obtained from the adult subjects and from the parents
of the paediatric patients. Informed assent was also obtained
from older children who were deemed capable of
understanding the nature of the study. The BISCUIT study is
publically registered on the United Kingdom Clinical
Research Network Portfolio (9633).
2.2. Preparation of samples for pyrosequencing
Biopsy DNAwas quantified by Nanodrop mass spectropho-
tometry before dilution to 25 ng/ml. Initial PCR amplification
was undertaken with FastStart High Fidelity PCR reagents
(Roche, Penzberg, Germany) utilising a per-reaction mix con-
taining 50 ngDNA template. The 18S rDNA primers were taken
fromOtt et al., [7]. No identifier was added to the reverse primer.
Hence the 540 bp PCR product was flanked by a 40 bp fusion
primer/multiplex identifier sequence at the forward end and a
30 bp fusion primer at the reverse end (Table 1). After confir-
mation of successful PCR amplification, products were purified
as per the recommendedAgencourtAMPure (BeckmanCoulter,
Beverly,MA, USA) purificationmethod for 454 sequencing and
sequenced on Roche 454 Titanium (454 life sciences, Branford,
CT, USA) by NewGene (Newcastle, UK).
2.3. Bioinformatic and statistical analysis
Data analysis of the 454 sequence data was performed
using QIIME version 1.3.0 workflow for 18S data using the
Qiime compatible version of the silva-104 release (down-
loaded from http://www.arb-silva.de/download/archive/qiime/)
for template based alignment and taxonomic assignment: Se-
quences were binned according to sample-specific barcode,
denoised (fast denoiser) and clustered with uclust into de-novo
operational taxonomic units (OTUs) at 97% sequence simi-
larity. Representative sequences were picked for each OTU
and aligned with Pynast using the Silva template alignment
core_Silva_aligned.fasta and chimera check was performed
with ChimeraSlayer for removal of potential chimeric se-
quences. Taxonomy assignment of each OTU was performed
by blasting against the taxonomic mapping file Silva_tax-
a_mapping_104set_97_otus.txt followed by construction of
OTU tables at different taxonomic levels. OTU tables were
rarefied at 3000 and results were plotted at phylum and genus
level. All novel sequence data was deposited at NCBI's
Sequence Read Archive under accession number PRJEB7438.
2.4. Quantitative real time PCR
Quantitative PCR was done to estimate the amount of
fungal rDNA present in all seven paediatric biopsy samples (6
IBD and 1 control) and three adult biopsy control samples.
The 18S region was amplified from 50 ng of sample DNA
using methods described previously [8]. Standard curve was
generated from 10-fold serial dilutions of amplified fungal 18S
rRNA genes from Candida albicans strain.
3. Results
A total of 37 paediatric patient colonic biopsies were
included within the study. This included 12 control patients,
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13 with CD and 12 with UC. Fungal DNA was amplifiable
from 8 patient samples, 6 children with a diagnosis of IBD e 4
with Crohn's disease, 2 children with ulcerative colitis and 2
children without IBD.
Fungal diversity was assessed in all paediatric samples
alongside four adult samples to act as a further comparison.
The adult samples comprised 2 patients with ulcerative colitis
and 2 patients with negative colonoscopy findings. Fungal
DNA could be amplified in one of the adult patients with de-
novo UC and both the adult controls.
Pyrosequencing generated ~90,000 individual sequencing
reads in total with a mean yield of 5245 reads per sample after
bioinformatic processing but before rarefaction. The minimum
read score was BISCUIT 27 with 3385 reads therefore rare-
faction analysis was performed at a threshold of 3000 reads to
allow subject-to-subject comparison. Two patient samples
(BISCUIT 64 and 1UC15) were discarded from further anal-
ysis as sequence data was confirmed to be Eukaryotic but
could not subsequently be matched to fungi. Almost all se-
quences from both patients were identical and matched only to
uncultured ‘Banisveld eukaryote’ (~72%), identified from
Banisveld water and thought to relate to a distinct phylum
[19].
Comparisons were made at both phylum and genus levels
(Figs. 1 and 2). Phylum level analysis indicated that fungal
sequences almost exclusively belonged to the Ascomycota and
Basidiomycota phyla (Fig. 1). The most abundant phylum was
Basidiomycota which was responsible for 100% of detectable
fungal sequences in 5 of the 6 paediatric IBD patient samples
(3/4 CD and 2/2 UC). In comparison the phylum data from the
three adult samples showed that the two healthy control
samples comprised >80% Ascomycota sequences whilst the
UC patient contained exclusively Basidiomycota sequences.
Genus level analysis was undertaken to compare the
Basidiomycota sequences between the paediatric IBD patient
samples (BISCUIT 31, 62, 89, 33, 104; Fig. 2). The number of
genera detected in paediatric samples varied from 3 to 8
genera and showed that both UC patients and one of the CD
patient samples were predominated by Corticiales sequences
(Fig. 2). Adult samples contained between 7 and 9 genera. The
Corticiales are one of the most ecologically diverse groups of
Basidiomycota containing saprobes, plant and fungal patho-
gens, and lichens. The other 2 CD patients were predominated
by an uncultured Basidiomycota sequence (BISCUIT 31) and
an Auriculariales sequence (BISCUIT 62). The remaining two
paediatric patient samples (BISCUIT 1 (CD) and BISCUIT 27
(control)) were heavily represented by Dothideomyceta spe-
cies, although the CD patient also contained some unclassified
Ascomycota sequences (~24%). When genus level analysis
was explored within the adult samples, there was
Table 1
List of fungal 18S rRNA specific Next Generation sequencing primers.
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Fig. 1. Individual patient phylum-level diversity assessment as stacked bars.
Fig. 2. Individual patient genus-level diversity assessment as stacked bars.
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representation from more genera than in the paediatric sam-
ples. There was no similarity between individual diversity
profiles; the control patients overlapped in containing Dothi-
deomyceta species with adult GH4 also containing unidenti-
fied Ascomyceta, Saccharomycetales, Agaricales and
Oxyporus. Adult GH9 also contained Botryobasidiaceae and
Trametes. Patient 2UC21 (adult de-novo UC) contained
Agaricales, Auriculariales, Oxyporus, Trametes and uncul-
tured environmental Basidiomycota species.
Quantitative PCR to document relative fungal load was
performed on all fungal positive biopsy samples and the re-
sults are summarised in Supplementary Table 2. Five out of
the seven paediatric samples showed much lower fungal load
as compared to the adult samples. The two samples which
showed comparable results were both from patients with CD
(BISCUIT1 and BISCUIT89).
4. Discussion
This study elucidates the fungal microbiome or mycobiome
in de-novo paediatric IBD patients. It is quite interesting to
note that an amplified fungal PCR product was available for
only 8 of the 37 paediatric subjects. This could potentially be
due to the DNA extraction method, which was optimised for
bacterial DNA extraction. The extraction protocol did not
subject biopsy samples to mechanical disruption, which is
recommended for some fungal species. Nevertheless, a variety
of fungal species were identified. This cohort has been subject
to an extensive (and successful) bacterial diversity analysis by
next-generation sequencing which has been reported else-
where, and the relative paucity of fungi in this cohort is indeed
a novel finding [20]. It is possible that aspects of fungal di-
versity have therefore been under-reported within this study
due to these limitations, however biopsy samples from both
the paediatric and adult cohorts were processed in the same
way therefore comparisons made between the various study
groups reflects genuine differences. It is also possible that the
low fungal diversity reported in this study is a confounder of
bowel preparation prior to colonoscopy, which all recruits
were subjected to. Whilst this may well be the case, it has not
impacted to a similar degree on reported bacterial diversity in
the same cohort [20]. It would also be difficult to ethically
justify accessing the colonic mucosa for research sampling in
children without adequate bowel preparation, hence these
children were undergoing colonoscopy for diagnostic purposes
and bowel preparation was therefore essential.
The evolution of the fungal microbiome from childhood to
adulthood is not known, but it can be surmised that with
increased and varied dietary exposure, adults might have a
greater quantity and diversity of fungi in their lumen. This is
clearly demonstrated with all adults in this study showing higher
fungal loads than themajority of children. An increased diversity
was demonstrated in the two adult controls that were studied.
Clearly a larger adult study is required to support this finding.
The single paediatric CD recruit with an Ascomycota pre-
dominance was clinically reviewed in relation to the other IBD
recruits in this study with respect to any critical differences
that might explain this finding. All the CD biopsies amplified
in this study were taken from macroscopically and micro-
scopically inflamed sites and from recruits with granulomatous
changes somewhere in their gastrointestinal tract, though not
necessarily at the same site as sampled. Perhaps intriguingly,
BISCUITs 31, 62 and 89 (Basidiomycota-predominant) had
endoscopic evidence of aphthous ulceration at the site sampled
for microbial analysis whereas BISCUIT 1 had inflamed mu-
cosa with erythema and mucosal breaks but no ulcers, though
granulomata and chronic inflammation were evident on his-
tology. Bacterial diversity assessment from BISCUIT 1 was
not dissimilar at phylum-level to the other CD recruits [20].
Clearly the small number of cases represented in this study,
and single incidence of an absence of aphthous ulceration and
coincidental Ascomycota predominance prevent any firm
conclusion being drawn, but the association of microbial/
fungal changes with endoscopic/microscopic disease should
be a direction for further research.
The current paradigm in the pathogenesis of IBD suggests
a perturbation in the relationship of the host innate immunity
and the resident luminal gut microbiota. This study has shown
a distinct dichotomy in the fungal microbiota between control
patients and patients with IBD with a predominance of
Ascomycota sequences (>80% of sequences in all patients) in
the former group whilst a majority of IBD patients (6/7)
contained exclusively members from the Basidiomycota
phylum. Nevertheless, it is acknowledged that this is a small
study and further studies are needed to validate these findings.
The biopsy samples from these patients were assiduously
collected prior to the institution of immunosuppressive treat-
ment and without the co-administration of antibiotics and
probably therefore represents the native condition as accu-
rately as ethically permissible in both cases and controls. This
stringency in case selection is critical in the assessment of the
fungal microbiome. One of the key members of Ascomycetes,
Candida is a normal commensal in the gut, which has been
documented to overgrow in patients treated with antibiotics
[21]. Therefore this shift from the Ascomycota-predominant
microbiota in normal subjects to a distinctly different fungal
spectrum with predominance of Basidomycetes in patients
with de-novo IBD without the conflicting influence of
immunosuppression or antibiotics might have pathogenic
relevance.
Fungal DNA accounts for around 0.02% of the entire
mucosa-associated microbiota as assessed from quantitative
analyses from mucosal biopsies [8]. The fact that only 8 out of
the paediatric cohort of 37 patients that were included in the
previously published bacterial diversity study were positive for
fungal PCR and could therefore be included in this study, sup-
ports the challenge of assessing fungal diversity within mucosal
samples. The finding of distinctly lower mucosal fungal load in
the paediatric cohort could partly explain this difficulty. A
recent fungal mycobiome analysis of healthy subject faecal
samples demonstrated positivity in all subject samples tested
(around 100 subjects) finding 66 genera, with generally mutu-
ally exclusive presence of either the phyla Ascomycota or
Basiodiomycota [22]. The difference in methodology of this
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study, which targeted the ITS region and our study and that by
Ott et al that utilised amplification of the 18S rRNA needs to be
acknowledged. Despite this, the findings reflects the data from
our study in terms of phylum diversity on an individual basis. It
also potentially highlights the fact that most fungal species
within the gut are not associated with the mucosa, remaining
predominantly within the luminal contents and most likely
having limited interaction with the host. We maintain that in
terms of clinical relevance, assessing diversity within fungal
species that are associated with mucosal tissues, especially
when assessing diversity in relation to IBD, a mucosal disease,
is the most appropriate sample choice.
It is difficult to ascertain if changes to the fungal compo-
nent have an impact on the final genesis of inflammation.
Other aspects of the immune response may however explain
changes that occur in the fungal microbiome. There has been
plenty of interest in the role of one of the key members of the
phylum Ascomycota, namely S. cerevisiae. The role of Anti-S.
cerevisiae antibodies (ASCA) has been found to be an
important phenotypic determinant, especially in CD patients
[13]. These antibodies may be as a result of loss of tolerance
against this fungus or another member of the phylum Asco-
mycota, perhaps C. albicans [23]. If the loss of tolerance hy-
pothesis can be extended to the Ascomycota phylum it may
explain why there is less representation in IBD patients and a
relative shift towards Basidomycetes. Our study does not have
the strength of numbers to definitely prove this hypothesis but
it indicates that a radical shift occurs in the fungal microbiota
of patients with IBD as opposed to controls, however with the
caveat that fungal DNA amplification and diversity assessment
appears more limited than conventional bacterial approaches.
The initiating event in IBD is still a matter of debate and it is
tantalising to suggest that this may in some cases be an
inappropriate response to a fungus.
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